Cart
sales@molnova.com
NCGC00135472
CAS No. 862811-76-5
NCGC00135472( —— )
Catalog No. M34666 CAS No. 862811-76-5
NCGC00135472 (DRV1 (GPR32) agonist C2A) is a human Resolvin DI receptor DRV1 agonist with pro-catabolic properties that activates the human soluble protein D1 receptor DRV1/GPR32 receptor in beta-blocker and cAMP assays with EC50s of 0.37 uM and 0.05 uM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 787 | In Stock |
|
| 10MG | 1074 | In Stock |
|
| 25MG | 1511 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2325 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 4557 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNCGC00135472
-
NoteResearch use only, not for human use.
-
Brief DescriptionNCGC00135472 (DRV1 (GPR32) agonist C2A) is a human Resolvin DI receptor DRV1 agonist with pro-catabolic properties that activates the human soluble protein D1 receptor DRV1/GPR32 receptor in beta-blocker and cAMP assays with EC50s of 0.37 uM and 0.05 uM, respectively.
-
DescriptionNCGC00135472 (DRV1 (GPR32) agonist C2A) is a human Resolvin DI receptor DRV1 agonist with pro-catabolic properties that activates the human soluble protein D1 receptor DRV1/GPR32 receptor in beta-blocker and cAMP assays with EC50s of 0.37 uM and 0.05 uM, respectively.NCGC00135472 induces in cells overexpressing recombinant DRV1 rapid impedance changes that stimulate phagocytosis of serum-treated zymoglycans.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number862811-76-5
-
Formula Weight364.35
-
Molecular FormulaC20H14F2N4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=C(N=C2N=CC=CN12)C1=CC(NC(=O)C2=CC=C(F)C(F)=C2)=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
AU-224
AU-224 is an orally available benzamide derivative that is a potent gastrointestinal prokinetic.
-
Deferoxamine mesylat...
An iron chelator that binds iron and aluminium; increases HIF-1α transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
